Pharmaceutical - Inflammatory diseases, Research

Filter

Popular Filters

Positive Ph III data for AstraZeneca’s lesinurad in gout patients

17-11-2014

Anglo-Swedish pharma major AstraZeneca has presented positive top-line results of two pivotal Phase III…

allopurinolAnti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

Insulin offers new hope for the treatment of acute pancreatitis

22-08-2014

Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting…

DiabetesInflammatory diseasesPancreas disordersPharmaceuticalResearchUK

Lilly’s ixekizumab shows superiority over etanercept and placebo in Ph III

Lilly’s ixekizumab shows superiority over etanercept and placebo in Ph III

21-08-2014

US pharma major Eli Lilly’s investigational medicine ixekizumab was superior to etanercept and placebo…

Eli LillyInflammatory diseasesixekizumabPharmaceuticalRegulationResearch

$5 million milestone for India’s Glenmark from Sanofi

$5 million milestone for India’s Glenmark from Sanofi

15-04-2014

Indian drugmaker Glenmark Pharmaceuticals says it has informed the Stock Exchange that it has received…

FinancialGlenmark PharmaceuticalsInflammatory diseasesPharmaceuticalResearchSanofi

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

NovaSAID partners with Cadila to develop inflammation and pain therapies

10-01-2014

Swedish research based company NovaSAID (a Karolinska Development portfolio firm) and Cadila Pharmaceuticals,…

Cadila PharmaceuticalsInflammatory diseasesNeurologicalNovaSAIDPharmaceuticalResearch

Shield Therapeutics’ ST10 delivers robust results in AEGIS Ph III program

07-01-2014

Independent UK pharma firm Shield Therapeutics has announces strongly positive top-line data from the…

HematologyInflammatory diseasesPharmaceuticalResearchShield TherapeuticsST10

AstraZeneca lesinurad meets Ph III goal in gout patients

AstraZeneca lesinurad meets Ph III goal in gout patients

16-12-2013

Anglo-Swedish drug major AstraZeneca has released positive top-line results from LIGHT, a Phase III…

Anti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

SOBI updates on Kepivance and SOB1002 development

SOBI updates on Kepivance and SOB1002 development

05-11-2013

At its Capital Market Day event on November 5, Swedish Orphan Biovitrum shared information regarding…

Inflammatory diseasesKepivanceKiobrinaOncologyPharmaceuticalResearchSOB1002SobiSwedish Orphan Biovitrum

Vectura and UCB to collaborate on severe inflammatory disease

Vectura and UCB to collaborate on severe inflammatory disease

30-09-2013

Vectura and UCB have entered into a collaboration for the development of an innovative biologic immuno-modulatory…

BiotechnologyEuropeInflammatory diseasesPharmaceuticalResearchRespiratory and PulmonaryUCBVectura

Teijin and Amgen join forces on autoimmune disease research

31-07-2013

Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

XOMA's partner Servier launches proof-of-concept clinical program for gevokizumab

25-06-2013

US drug developer XOMA Corp (Nasdaq: XOMA) says that its development partner, French independent drugmaker…

Anti-Arthritics/RheumaticsgevokizumabInflammatory diseasesPharmaceuticalResearchServierXOMA Corp

Teva and Active Biotech to move forward with laquinimod on positive Ph IIa results in active lupus nephritis

13-06-2013

Israel's Teva Pharmaceutical Industries (NYSE: TEVA) and Swedish partner Active Biotech (OMX NORDIC:…

Active BiotechInflammatory diseaseslaquinimodNephrology and HepatologyPharmaceuticalResearchTeva Pharmaceutical Industries

AbbVie to pay $50 million to expand GLPG0634 deal with Galapagos to Crohn's disease

17-05-2013

US drugmaker AbbVie (NYSE: ABBV) says it is extending its deal with Belgium-based Galapagos (Euronext:…

AbbVieAnti-Arthritics/RheumaticsGalapagosGLPG0634Inflammatory diseasesLicensingPharmaceuticalResearch

AstraZeneca plans more job cuts; inks $240M-plus deal with Moderna; expands alliance with Karolinska Institutet

21-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN), ahead of its Investor Day briefing in New York later…

AstraZenecaCardio-vascularFinancialImmunologicalsInflammatory diseasesLicensingModerna TherapeuticsOncologyPharmaceuticalResearch

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S

10-10-2012

Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Novo Nordisk collaborates with Oxford University on RA and other inflammatory diseases research

25-04-2012

Departing from its core competence, diabetes, Danish insulin giant Novo Nordisk (NOV: N) and the Kennedy…

Anti-Arthritics/RheumaticsInflammatory diseasesNovo NordiskPharmaceuticalResearch

GSK exercises option for Galapagos drug candidates

21-02-2012

Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Back to top